trending Market Intelligence /marketintelligence/en/news-insights/trending/ibaML3xlLKbJ1osNpjzSGw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Roche agrees to acquire genetic code analysis enzyme from Codexis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Roche agrees to acquire genetic code analysis enzyme from Codexis

Roche Holding AG agreed to acquire worldwide rights of Codexis Inc.'s EvoT4, an enzyme that is used to analyze a patient's genetic code and how their cells express their genes as proteins.

EvoT4 was developed using Codexis' proprietary protein engineering platform CodeEvolver.

Redwood City, Calif.-based Codexis is a protein engineering company and develops proteins for manufacturing pharmaceuticals, fine chemicals and industrial enzymes.

Financial details of the agreement were not disclosed.